Diplomat Pharmacy Inc.’s stock value plummeted recently after the company said it would delay the release of its fourth-quarter and full-year earnings results — primarily because of struggles with its PBM business. Some of the issues Diplomat is facing, experts tell AIS Health, are indicative of how difficult it is for smaller players to compete in a landscape where large, integrated companies now dominate.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.